紫杉特尔联合卡培他滨治疗晚期胃癌的初步报告  

The Clinical Report of The Patients of Resistant Advanced gastric cancer Treated with docetaxcl plus cisplatinfluorouracil

作　　者：林大任[1] 李明毅[1] 谭洁媚[1] 刘秀娟[1] 

机构地区：[1]广东省江门市中心医院,江门529000

出　　处：《中国医药导报》2006年第6期5-7,共3页China Medical Herald

摘　　要：目的了解紫杉特尔联合卡培他滨化疗方案治疗晚期胃癌的疗效和毒副作用。方法自2001年10月-2005年1月,有41例晚期胃癌病人入组,口服希罗达每日1650mg/(m2·d),连服1-14天,紫杉特尔75mg/m2静脉滴注,第1天应用,每3周为1周期,连用4周期;治疗结束2周后评价疗效、毒副反应。结果全组可评价病例39例,其中CR3例,PR18例,总有效率53.8%。主要毒副反应为骨髓抑制和手足综合征,绝大部分病人均能耐受。结论紫杉特尔联合卡培他滨化疗方案是目前治疗晚期胃癌较理想的方案。Objective To study the effcacy and adverse effect of patients of locally advanced gastric cancer treated with docetaxcl plus cisplatinfluorouracil.Methods From October,2000 to January,2005,forty-one patients of locally advanced gastric cancer were randomized into our group:they were treated with Xeloda 1650mg/(m^2·d) p.o.for fourteen days,docetaxcl 75mg/m^2,intravenous infusion d1.The two regimens were repeated every three weeks and totally two to four cycles.The evaluation is performed two weeks after the completion of chemotherapy.Results Thirty-nine patients had evaluable lesions.The CR+PR is 53.8%,The main toxicity is myelosuppression and hand-foot syndrome.But it could be well tolerated by most patients.Conclusion Now docetaxcl plus cisplatinfluorouracil is more effective in the treating the patients of locally advanced gastric cancer.

关 键 词：胃肿瘤 化疗 紫杉特尔 卡培他滨 

分 类 号：R[医药卫生]